Allied Corp. (ALID) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Allied Corp. (ALID) trades at $0.0005 with AI Score 39/100 (Grade D). Allied Corp. is a medical cannabis production company focused on cannabinoid health solutions in the U. S. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for ALID: ALID does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALID against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ALID: 3/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Allied Corp. (ALID) Healthcare & Pipeline Overview
Allied Corp. specializes in the research and production of cannabinoid health solutions, offering a range of hemp-derived products while navigating the evolving landscape of the medical cannabis industry.
What Is the Investment Thesis for ALID?
Allied Corp. presents a unique investment thesis driven by its innovative product portfolio and strategic focus on cannabinoid health solutions. With a market cap currently at $0.00B and a profit margin of -14807.6%, the company is in a critical phase of development, particularly with its ALID 10 and ALID 11 products targeting PTSD, which could tap into a significant and underserved market. The U.S. medical cannabis market is projected to grow substantially, driven by increasing acceptance and regulatory changes. As the company continues to refine its product offerings and expand its distribution channels, it is poised to capture a larger share of this expanding market. However, investors should remain cognizant of the inherent risks associated with the cannabis industry, including regulatory challenges and market volatility. Monitoring these factors will be essential to assess the company's ability to achieve its growth objectives and improve financial performance.
Based on FMP financials and quantitative analysis
ALID Key Highlights
- Market cap currently at $0.00B reflects early-stage development in the cannabis industry.
- Profit margin of -14807.6% indicates significant investment in growth and product development.
- Gross margin of -2027.5% highlights the challenges in scaling operations and achieving profitability.
- Diverse product portfolio includes CBD tinctures, gummies, and topical applications targeting various health needs.
- Ongoing Phase I clinical trials for ALID 10 and ALID 11 represent potential future revenue streams.
Who Are ALID's Competitors?
ALID is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CGC Canopy Growth Corporation | $0.94 | +0.78% | $398M | 46 |
| APHA APHA | $15.27 | -1.04% | 56 | |
| CRON Cronos Group Inc. | $2.80 | +0.36% | $1.05B | 62 |
| TLRY Tilray Brands, Inc. | $4.23 | -1.63% | $508M | 47 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.14 | +0.21% | $40.3M | 61 |
| MNNGF Baijin Life Science Holdings Limited | $0.07 | +0.00% | $58.0M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALID's Key Strengths?
- Innovative product offerings tailored to consumer health needs.
- Strong focus on research and development for new therapeutic solutions.
- Established presence in the growing medical cannabis market.
- Diverse product portfolio enhancing market reach.
What Are ALID's Weaknesses?
- Negative profit margins indicating financial challenges.
- Limited brand recognition compared to larger competitors.
- Dependence on regulatory approval for pharmaceutical products.
- Potential liquidity issues as an OTC listed company.
What Could Drive ALID Stock Higher?
- Completion of Phase I clinical trials for ALID 10 and ALID 11, which could lead to significant advancements in PTSD treatment.
- Expansion of product distribution channels in the U.S. market to capture increasing consumer demand.
- Continuous development of innovative hemp-derived health products to enhance market competitiveness.
- Strategic partnerships aimed at enhancing market reach and product credibility.
- Monitoring and adapting to regulatory changes that could impact market opportunities.
What Are the Key Risks for ALID?
- Financial-distress signal — its Altman Z-Score of -48.13 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory changes that could affect product approval and market access.
- Competition from established players in the cannabis industry impacting market share.
- Economic downturns that may reduce consumer spending on wellness products.
- Market volatility leading to fluctuations in stock price and investor sentiment.
What Are the Growth Opportunities for ALID?
- Expansion into U.S. Markets: Allied Corp. is strategically positioned to expand its market presence in the U.S., where the medical cannabis market is projected to grow at a CAGR of 22.9% through 2025. By enhancing its distribution channels and increasing product availability, the company can capture a significant share of this lucrative market, particularly with its innovative product offerings.
- Development of Pharmaceutical Products: The ongoing Phase I clinical trials for ALID 10 and ALID 11 targeting PTSD represent a critical growth opportunity. The global market for PTSD treatments is substantial, estimated to reach $7.5 billion by 2027. Successful development and approval of these products could provide Allied Corp. with a competitive edge and a new revenue stream.
- Innovative Product Development: Allied Corp.'s commitment to research and development in cannabinoid health solutions allows for the introduction of new products tailored to consumer needs. With the wellness trend driving demand for natural health products, the company can leverage its expertise to create innovative offerings that resonate with health-conscious consumers.
- Strategic Partnerships and Collaborations: Forming strategic alliances with healthcare providers, research institutions, and distribution partners can enhance Allied Corp.'s market reach and credibility. Collaborations can facilitate access to new markets and resources, accelerating growth and product development timelines.
- Regulatory Advancements: As regulations surrounding cannabis continue to evolve, Allied Corp. stands to benefit from increased acceptance and potential market expansion. Staying ahead of regulatory changes and adapting its business model accordingly can position the company favorably in the competitive landscape.
What Opportunities Does ALID Have?
- Expansion into lucrative U.S. medical cannabis market.
- Development of new pharmaceutical products targeting unmet medical needs.
- Growing consumer acceptance of cannabinoid health solutions.
- Strategic partnerships to enhance market presence and credibility.
What Threats Does ALID Face?
- Increasing regulatory scrutiny in the cannabis industry.
- Market volatility and competition from established players.
- Potential changes in consumer preferences and trends.
- Economic downturns affecting consumer spending on wellness products.
What Are ALID's Competitive Advantages?
- Innovative product development focused on cannabinoid health solutions.
- Established brand presence in the evolving cannabis market.
- Strong commitment to research and clinical trials for product efficacy.
- Diverse product portfolio catering to various consumer needs.
- Ability to adapt to regulatory changes in the cannabis industry.
What Does ALID Do?
Founded in 2013 and headquartered in Kelowna, Canada, Allied Corp. is a medical cannabis production company that engages in the research, development, and production of cannabinoid health solutions primarily in the United States. The company has evolved to offer a wide array of hemp-derived natural health products designed for various therapeutic applications. Among its flagship offerings are Liberty, a hemp-derived cannabidiol (CBD) tincture, and Tactical Hydration, a CBD-infused electrolyte replacement drink, which cater to health-conscious consumers. Allied Corp. also produces innovative products such as FIZZ Tablets, Battle Balm, and Quick Hit gummies under the Tactical Relief brand. Additionally, its Equilibrium Bio brand features Hydrosport CBD Drink and tinctures, while the MaXXa brand includes skincare products like Skin Structure and Eye Recover. Currently, Allied Corp. is advancing its pharmaceutical pipeline with ALID 10 and ALID 11, which are in Phase I clinical trials aimed at treating post-traumatic stress disorder (PTSD). This diversification into pharmaceuticals highlights the company's commitment to expanding its market presence and addressing unmet medical needs. As the cannabis industry continues to grow, Allied Corp. positions itself as a key player with a focus on innovation and quality in the rapidly evolving landscape of cannabinoid-based health solutions.
What Products and Services Does ALID Offer?
- Research, develop, and produce cannabinoid health solutions.
- Offer a variety of hemp-derived natural health products.
- Provide CBD-infused drinks, tinctures, and topical applications.
- Develop pharmaceutical products targeting specific health conditions.
- Focus on innovation and quality in product offerings.
- Engage in clinical trials for new therapeutic solutions.
How Does ALID Make Money?
- Generate revenue through the sale of hemp-derived health products.
- Develop pharmaceutical products for specific medical conditions.
- Leverage research and development to create innovative product lines.
- Expand distribution channels to reach a wider consumer base.
- Engage in partnerships to enhance product credibility and market presence.
What Industry Does ALID Operate In?
The cannabis industry, particularly the medical segment, is experiencing rapid growth, driven by increasing legalization and acceptance of cannabis products across various jurisdictions. The global medical cannabis market is projected to reach $56.7 billion by 2025, with a compound annual growth rate (CAGR) of 22.9%. Allied Corp. operates within this dynamic environment, competing against established players and new entrants in the specialty and generic drug manufacturing sector. The company's focus on cannabinoid health solutions positions it well to capitalize on the growing demand for natural health products and innovative therapies in the healthcare industry.
Who Are ALID's Key Customers?
- Health-conscious consumers seeking natural health products.
- Individuals with specific health conditions looking for cannabinoid solutions.
- Retailers and distributors of wellness products.
- Healthcare professionals recommending cannabinoid therapies.
- Patients participating in clinical trials for new products.
Company Profile
Allied Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Kelowna, CA. The company is led by CEO Paul Bullock. ALID has traded publicly since 2019.
How Allied Corp. Is Valued
Relative to its peer group, ALID's quantitative score of 39/100 is below the peer average of 55/100.
ROE 261%Key Financial Metrics
Return on equity for Allied Corp. stands at 261.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
Allied Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -48.13 places it in the distress zone, a signal of elevated financial risk.
Net buyingInsider Activity
The most recent 2 insider filings for Allied Corp. break down as 0 sales and 2 purchases. On net that is roughly 80K shares acquired (about $37K) — insiders putting money in tends to read as conviction.
ALID Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative product offerings tailored to consumer health needs.
- Strong focus on research and development for new therapeutic solutions.
- Established presence in the growing medical cannabis market.
- Diverse product portfolio enhancing market reach.
Bear Case
- Negative profit margins indicating financial challenges.
- Limited brand recognition compared to larger competitors.
- Dependence on regulatory approval for pharmaceutical products.
- Potential liquidity issues as an OTC listed company.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ALID Latest News
No recent news available for ALID.
ALID Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALID.
Price Targets
Wall Street price target analysis for ALID.
ALID MoonshotScore
What does this score mean?
The MoonshotScore rates ALID 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Paul Bullock
CEO
Paul Bullock has extensive experience in the cannabis industry and has been instrumental in guiding Allied Corp. since its inception in 2013. With a strong background in business management and strategic development, he has led the company through various phases of growth and product innovation. His leadership is characterized by a commitment to research and development, particularly in cannabinoid health solutions.
Track Record: Under Paul Bullock's leadership, Allied Corp. has developed a diverse product portfolio and initiated clinical trials for innovative pharmaceutical products. His strategic vision has positioned the company to capitalize on emerging opportunities in the medical cannabis market.
ALID OTC Market Information
The OTC Other tier indicates that Allied Corp. is not listed on major exchanges like NYSE or NASDAQ, which typically have stricter reporting requirements and higher visibility. Companies in this tier may have less liquidity and fewer resources for investor communication.
- OTC Tier: OTC Other
- Limited liquidity may hinder the ability to buy or sell shares without impacting the stock price.
- Less stringent reporting requirements can lead to less transparency for investors.
- Regulatory risks associated with the cannabis industry can affect business operations and market perception.
- Market volatility can lead to significant price fluctuations.
- Verify the company's financial health through available reports.
- Assess the management team's experience and track record.
- Monitor regulatory developments in the cannabis industry.
- Evaluate the competitive landscape and market positioning.
- Review product offerings and pipeline developments.
- Established brand presence in the cannabis industry.
- Ongoing clinical trials for pharmaceutical products indicating commitment to research.
- Partnerships or collaborations with reputable organizations in the healthcare sector.
ALID Healthcare Stock FAQ
What does the AI Score mean for ALID?
ALID holds an AI Score of 39/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Allied Corp. is a medical cannabis production company focused on cannabinoid health solutions in the U.S. It offers a diverse range of hemp-derived products and is currently developing …
What does Allied Corp. do?
Allied Corp. is a medical cannabis production company that specializes in the research, development, and production of cannabinoid health solutions. The company offers a diverse range of hemp-derived products, including CBD tinctures, gummies, and topical applications, targeting various health needs. Additionally, Allied Corp. is developing pharmaceutical products aimed at treating conditions such as post-traumatic stress disorder (PTSD), positioning itself as a key player in the evolving cannabis industry.
How does Allied Corp. navigate regulatory approval processes?
Allied Corp. actively engages with regulatory bodies to ensure compliance with applicable laws and standards in the cannabis industry. The company follows rigorous protocols for product development, particularly for its pharmaceutical offerings, which are currently in clinical trials. By maintaining transparency and adhering to regulatory guidelines, Allied Corp. aims to facilitate smoother approval processes for its products, ultimately enhancing its market position.
What are the main risks for ALID?
Allied Corp. faces several risks inherent to the cannabis industry, including regulatory changes that could impact product approvals and market access. Additionally, the company operates in a highly competitive landscape, which could affect its market share and pricing strategies. Economic downturns may also reduce consumer spending on wellness products, while market volatility can lead to significant fluctuations in stock price, posing challenges for investors.
What are the key factors to evaluate for ALID?
Allied Corp. (ALID) holds an AI score of 39/100 (low). Not financial advice.
How frequently does ALID data refresh on this page?
ALID's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ALID's recent stock price performance?
Allied Corp. (ALID) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings tailored to consumer health needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALID overvalued or undervalued right now?
Allied Corp. (ALID) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ALID before investing?
Before investing in Allied Corp. (ALID), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial metrics are subject to change and should be verified through official reports.